Fortress Biotech, Inc.
NASDAQ:FBIO · NASDAQ Capital Market
+$0.01 today
Vol 0.37M · Avg 0.43M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:FBIO · Revenue to Net Income
Key Ratios
Analysis
$66.2M of revenue converted into $127.8M of net income for the selected period. Gross margin is 64.4% and net margin is 197.8%, showing how much revenue survives after costs and taxes. EPS is $3.18, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $63.3M +9.7% | $57.7M -31.8% | $84.5M +11.6% | $75.7M +10.1% | $68.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $20.9M +0.2% | $20.9M -8.8% | $22.9M -25.6% | $30.8M -4.1% | $32.1M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $42.3M +15.1% | $36.8M -40.3% | $61.6M +37.0% | $45.0M +22.5% | $36.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 66.9% +3.1pp | 63.8% -9.1pp | 72.9% +13.5pp | 59.4% +6.0pp | 53.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $11.9M -79.1% | $56.9M -46.4% | $106.1M -21.4% | $134.9M +4.7% | $128.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $96.4M +9.9% | $87.7M -3.6% | $91.0M -20.0% | $113.7M +30.9% | $86.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $112.6M -23.5% | $147.2M -27.8% | $204.0M -17.9% | $248.5M +10.3% | $225.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $4.7M +4.4% | $4.5M -25.6% | $6.0M -35.9% | $9.4M +37.7% | $6.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$20.2M +80.7% | -$104.5M +23.0% | -$135.7M +29.9% | -$193.7M -32.5% | -$146.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -31.9% +149.3pp | -181.2% -20.6pp | -160.6% +95.1pp | -255.7% -43.2pp | -212.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$70.2M +36.4% | -$110.4M +22.5% | -$142.3M +30.1% | -$203.6M -8.0% | -$188.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -111.0% +80.4pp | -191.4% -23.0pp | -168.4% +100.3pp | -268.8% +5.3pp | -274.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.5M -7.4% | $2.7M -10.7% | $3.0M +114.8% | $1.4M +115.4% | $649.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $8.7M -12.3% | $9.9M -20.7% | $12.5M -8.2% | $13.6M -10.9% | $15.3M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $36.7M +460.9% | -$10.2M +10.0% | -$11.3M -14.1% | -$9.9M -140.9% | $24.2M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$33.5M +72.2% | -$120.5M +21.5% | -$153.6M +28.0% | -$213.5M -29.9% | -$164.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -53.0% +156.0pp | -209.0% -27.2pp | -181.8% +100.0pp | -281.8% -42.9pp | -238.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$620.0K -298.7% | $312.0K -40.1% | $521.0K +16.0% | $449.0K -5.1% | $473.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | $6.8M +114.8% | -$46.0M +24.1% | -$60.6M +30.0% | -$86.6M -33.8% | -$64.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | 10.8% +90.5pp | -79.8% -8.0pp | -71.7% +42.6pp | -114.3% -20.2pp | -94.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +97.5% | -$3 +68.2% | -$8 +41.8% | -$15 -22.8% | -$12 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +97.5% | -$3 +68.2% | -$8 +41.8% | -$15 -22.8% | -$12 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $27.9M +34.2% | $20.8M +156.2% | $8.1M +36.9% | $5.9M +8.8% | $5.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $279.0M +1242.5% | $20.8M +156.2% | $8.1M +36.9% | $5.9M +8.8% | $5.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Vaxart, Inc.
NASDAQ:VXRT
$135.55M
Adagene Inc.
NASDAQ:ADAG
$134.41M
Gain Therapeutics, Inc.
NASDAQ:GANX
$71.66M
XBiotech Inc.
NASDAQ:XBIT
$71.34M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Nutriband Inc.
NTRB
$41.21M
CervoMed Inc.
CRVO
$22.68M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does FBIO generate?
Fortress Biotech, Inc. (FBIO) reported $63.26M of revenue in fiscal 2025.
Is FBIO profitable?
Fortress Biotech, Inc. (FBIO) reported $6.82M of net income, with a net margin of 10.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.